The Festival of Genomics, Biodata & AI returns to Boston at a critical moment for the US life sciences community. Funding pressures, rising development costs and intensifying competition are colliding with an unprecedented opportunity: the convergence of multi-omics, large-scale biodata and artificial intelligence.
To stay ahead, organizations must do more than generate data – they must integrate technologies, break down silos and translate insight into measurable progress, in research, drug discovery and translation into the clinic.
